218 related articles for article (PubMed ID: 37798904)
1. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities.
Creus-Bachiller E; Fernández-Rodríguez J; Magallón-Lorenz M; Ortega-Bertran S; Navas-Rutete S; Romagosa C; Silva TM; Pané M; Estival A; Perez Sidelnikova D; Morell M; Mazuelas H; Carrió M; Lausová T; Reuss D; Gel B; Villanueva A; Serra E; Lázaro C
Mol Oncol; 2024 Apr; 18(4):895-917. PubMed ID: 37798904
[TBL] [Abstract][Full Text] [Related]
2. Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population.
Patrizi S; Miele E; Falcone L; Vallese S; Rossi S; Barresi S; Giovannoni I; Pedace L; Nardini C; Masier I; Abballe L; Cacchione A; Russo I; Di Giannatale A; Di Ruscio V; Salgado CM; Mastronuzzi A; Ciolfi A; Tartaglia M; Milano GM; Locatelli F; Alaggio R
Clin Epigenetics; 2024 Jan; 16(1):9. PubMed ID: 38178234
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine.
Castellsagué J; Gel B; Fernández-Rodríguez J; Llatjós R; Blanco I; Benavente Y; Pérez-Sidelnikova D; García-Del Muro J; Viñals JM; Vidal A; Valdés-Mas R; Terribas E; López-Doriga A; Pujana MA; Capellá G; Puente XS; Serra E; Villanueva A; Lázaro C
EMBO Mol Med; 2015 May; 7(5):608-27. PubMed ID: 25810463
[TBL] [Abstract][Full Text] [Related]
4. A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.
Fernández-Rodríguez J; Creus-Bachiller E; Zhang X; Martínez-Iniesta M; Ortega-Bertran S; Guha R; Thomas CJ; Wallace MR; Romagosa C; Salazar-Huayna L; Reilly KM; Blakely JO; Serra-Musach J; Pujana MA; Serra E; Villanueva A; Ferrer M; Lázaro C
Mol Cancer Ther; 2022 Jul; 21(7):1246-1258. PubMed ID: 35511749
[TBL] [Abstract][Full Text] [Related]
5. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
Williams KB; Largaespada DA
Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
[TBL] [Abstract][Full Text] [Related]
6. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
[TBL] [Abstract][Full Text] [Related]
7. p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs.
Grit JL; McGee LE; Tovar EA; Essenburg CJ; Wolfrum E; Beddows I; Williams K; Sheridan RTC; Schipper JL; Adams M; Arumugam M; Vander Woude T; Gurunathan S; Field JM; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
Oncogene; 2024 May; 43(19):1411-1430. PubMed ID: 38480916
[TBL] [Abstract][Full Text] [Related]
8. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors.
Gong M; Ma J; Li M; Zhou M; Hock JM; Yu X
Neuro Oncol; 2012 Aug; 14(8):1007-17. PubMed ID: 22718995
[TBL] [Abstract][Full Text] [Related]
10. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
[TBL] [Abstract][Full Text] [Related]
11. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.
Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL
Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323
[TBL] [Abstract][Full Text] [Related]
12. VEGF and VEGFR family members are expressed by neoplastic cells of NF1-associated tumors and may play an oncogenic role in malignant peripheral nerve sheath tumor growth through an autocrine loop.
Bonsang B; Maksimovic L; Maille P; Martin N; Laurendeau I; Pasmant E; Bièche I; Deschamps J; Wolkenstein P; Ortonne N
Ann Diagn Pathol; 2022 Oct; 60():151997. PubMed ID: 35777330
[TBL] [Abstract][Full Text] [Related]
13. Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics.
Sugita S; Aoyama T; Emori M; Kido T; Takenami T; Sakuraba K; Terai K; Sugawara T; Tsujiwaki M; Hasegawa T
Diagn Pathol; 2021 Aug; 16(1):79. PubMed ID: 34461930
[TBL] [Abstract][Full Text] [Related]
14. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
[TBL] [Abstract][Full Text] [Related]
15. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
16. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
[TBL] [Abstract][Full Text] [Related]
17. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
[TBL] [Abstract][Full Text] [Related]
18. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
[TBL] [Abstract][Full Text] [Related]
20. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
